NCT02265406View on ClinicalTrials.gov

PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone

PHASE3CompletedINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

July 25, 2020

Study Completion Date

July 25, 2020

Conditions
Early Ventilation Acquired Pneumonia in Brain Injured Patients
Interventions
DRUG

Anti-Infective Agents

DRUG

Placebo

Trial Locations (8)

31059

Thomas GEERAERTS, Toulouse

35033

University Hospital of Rennes, Rennes

37000

Djilali ELAROUSSI, Tours

44093

University Hospital of Nantes, Nantes

49933

University Hospital of Angers, Angers

86021

University Hospital of Poitiers, Poitiers

Unknown

CHU, Bordeaux

CHRU, Montpellier

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT02265406 - PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone | Biotech Hunter | Biotech Hunter